Summary of Significant Accounting Policies - Additional Information (Details)		12 Months Ended
	Mar. 25, 2022 USD ($) Market	Dec. 31, 2022 USD ($) Institution ReportingUnits Segment Market	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Segment and Geographic Information
Number of operating segments | Segment		1
Revenue Recognition
Product sales, net		$ 50,037,106
Cash Equivalents
Cash Equivalents		$ 200,800,000
Concentration of Credit Risk
Number of financial institutions that hold the Company's cash | Institution		1
Business Combination
Intangible assets, Estimated period of benefit		10 years
Number of reporting units | ReportingUnits		1
Accounts Receivable, net
Accounts receivable, Allowance for credit loss		$ 0
Accounts receivable, reserves for variable consideration		$ 9,100,000
Equipment, net
Estimated useful life		3 years
Cost of Product Sales
Cost of product sales		$ 5,200,000
Payment terms		90 days or less
Sales		$ 0
Advertising costs		$ 35,300,000
Income Taxes
Effective tax rate		0.00%
Income tax benefit		$ 0	$ 0	$ 0
Ex-U.S. Markets
Cost of Product Sales
Sales		900,000
Sunosi
Revenue Recognition
Product sales, net		44,800,000
Cost of Product Sales
Sales		$ 44,800,000
Number of Asian markets | Market		12
Revenue milestones	$ 165,000,000	$ 165,000,000
Development milestones	$ 1,000,000	$ 1,000,000
Sunosi | Jazz Pharmaceuticals Plc
Business Combination
Intangible assets, Estimated period of benefit		10 years
Cost of Product Sales
Number of Asian markets | Market	12
Auvelity
Cost of Product Sales
Sales		$ 5,200,000
License agreement royalty as a percent of net sales		3.00%